Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Net Margin (2022 - 2025)

Historic Net Margin for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to 154.17%.

  • InMed Pharmaceuticals' Net Margin fell 215000.0% to 154.17% in Q3 2025 from the same period last year, while for Sep 2025 it was 171.13%, marking a year-over-year decrease of 338600.0%. This contributed to the annual value of 165.14% for FY2025, which is 18000.0% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Net Margin of 154.17% as of Q3 2025, which was down 215000.0% from 137.07% recorded in Q2 2025.
  • InMed Pharmaceuticals' 5-year Net Margin high stood at 14.56% for Q2 2023, and its period low was 1615.6% during Q4 2021.
  • For the 5-year period, InMed Pharmaceuticals' Net Margin averaged around 471.07%, with its median value being 180.61% (2023).
  • In the last 5 years, InMed Pharmaceuticals' Net Margin skyrocketed by 15143100bps in 2023 and then tumbled by -1359000bps in 2024.
  • Over the past 5 years, InMed Pharmaceuticals' Net Margin (Quarter) stood at 1615.6% in 2021, then soared by 72bps to 446.61% in 2022, then skyrocketed by 73bps to 119.19% in 2023, then plummeted by -94bps to 231.63% in 2024, then skyrocketed by 33bps to 154.17% in 2025.
  • Its last three reported values are 154.17% in Q3 2025, 137.07% for Q2 2025, and 168.12% during Q1 2025.